Physician profile
Benjamin Smith
NPI 1881905438
$78,218.68
in general payments reported to CMS, 2019-2025
12 companies · $6,769 in 2025
The $6,769 reported for 2025 was more than what a typical Orthopaedic Surgery of The Spine provider received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $14K · 2021: $15K · 2022: $9,464 · 2023: $28K · 2024: $4,252 · 2025: $6,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Travel and Lodging: $10K · Food and Beverage: $2,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,670.00 |
| Travel and Lodging | $10,228.89 |
| Food and Beverage | $2,165.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alphatec Spine, INC | $75,128.19 | 2020-2025 | Other - Miscellaneous, Solus Alif, Ltp |
| Medtronic, INC. | $1,896.65 | 2021-2025 | Mazor X System, Stealthstation S8 Platform, Unid_pass |
| Nuvasive, INC. | $700.60 | 2019 | |
| Zimmer Biomet Holdings, INC. | $130.20 | 2024 | Rosa |
| Stryker Corporation | $94.67 | 2019-2023 | Mako |
| Medtronic USA, INC. | $69.89 | 2019-2020 | |
| Baxter Healthcare | $53.40 | 2021-2024 | Perclot |
| Pacira Pharmaceuticals Incorporated | $48.64 | 2021 | |
| Depuy Synthes Sales INC. | $42.41 | 2020-2023 | Fibergraft Aeridyan Matrix |
| Bioventus LLC | $27.55 | 2019 | |
| Si-Bone, INC. | $13.50 | 2025 | |
| Pacira Therapeutics, INC. | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.